See every side of every news story
Published loading...Updated

Time Out: Jazz dismisses final patent claim involving cannabinoid epilepsy drug - Cannabis News World

Summary by Cannabis News World
MJ Biz reports Global pharma company Jazz Pharmaceuticals has ended patent claims related to its cannabinoid-based epilepsy drug, Epidiolex. The Ireland-based company, according to Green Market Report, filed its 2023 patent-enforcement lawsuit against a dozen alleged infringers, including: Alkem Laboratories API Pharma Tech Apotex Ascent Pharmaceuticals Biophore Pharma InvaGen Pharmaceuticals and its parent, Cipla USA Lupin MSN Pharmaceuticals P…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Cannabis News World broke the news in on Saturday, February 22, 2025.
Sources are mostly out of (0)